Stock Analysis·← Pickers

HCWB

HCW Biologics Inc.

HCW Biologics Inc. (HCWB) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 36.1, with 0/3 trend checks passing.

Price
$4.30
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
36.1
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

HCWB with MA50 and MA200

36.1227.4918.8610.241.6107/3110/2401/2204/1707/15
HCWB2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$6.93-37.97% vs price
MA200
$9.34-53.98% vs price
RSI (14)
36.1Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for HCWB

HCW Biologics Inc. (HCWB) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $4.30, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 38.0% and below the 200-day moving average by 54.0%.

Momentum and stretch context

HCWB currently has an RSI reading of 36.1, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing HCWB next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About HCW Biologics Inc.

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

Sector
Healthcare
Industry
Biotechnology
CEO
Hing C. Wong
Employees
35
Market cap
$1.5M
Beta
2.30
52-week range
$1.50 – $44.10
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
20 Jul 2021
ISIN
US40423R3030
CUSIP
40423R303
Company profile data from Financial Modeling Prep. HCWB listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about HCWB

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.

HCWB Stock Analysis: Downtrend, below MA50 & MA200, RSI 36 | MyStockHarbor